Colorectal Cancer
July 2022 Vol 13, No 7 | July 25, 2022
Colorectal cancer is the fourth most diagnosed cancer in the United States, representing 7.9% of all new cases.
February 2022 Vol 13, No 2 | March 4, 2022
Are you aware of the new screening guidelines?
October 2020 Vol 11, No 10 | October 6, 2020
There’s a new standard of care in the first-line setting for a subset of patients with advanced colorectal cancer.
August 2019 Vol 10, No 8 | August 5, 2019
The combination of the PD-1 inhibitor durvalumab and the CTLA-4 inhibitor tremelimumab added to best supportive care improved overall survival (OS) by >2 months compared with best supportive care alone in a phase 2 randomized trial of unselected patients with refractory colorectal cancer (CRC).
May 2019 Vol 10, No 5 | May 7, 2019
More targeted therapy options make their way into the updated guideline (version 1.2019) from the National Comprehensive Cancer Network (NCCN) for the management of metastatic colorectal cancer (CRC).
May 2019 Vol 10, No 5 | May 7, 2019
Updated results from the safety lead-in of the phase 3 BEACON CRC clinical trial show a mature median overall survival (OS) of 15.3 months with the triple-drug regimen of encorafenib, a BRAF inhibitor; binimetinib, a MEK inhibitor; and cetuximab, an epidermal growth factor receptor (EGFR) inhibitor, for the treatment of patients with metastatic colorectal cancer (CRC) and BRAF V600E mutation.
August 2017 Vol 8, No 8 | August 3, 2017
Using a “double whammy” of 2 HER2-directed therapies achieved a clinical benefit rate of 70% and an objective response rate (ORR) of 30% in patients with heavily pretreated, HER2-positive metastatic colorectal cancer (CRC), according to final results from the phase 2 HERACLES-A trial.
April 2017 Vol 8, No 4 | April 12, 2017
Adding vemurafenib to cetuximab and irinotecan prolonged progression-free survival (PFS) and improved the disease control rate in patients with BRAF V600E mutation–positive colorectal cancer (CRC).
December 2016 Vol 7, No 11 | November 28, 2016
Here is new information pertaining to this disease site for genetic testing and practice guidelines.
Tierra Amos, BS, Thomas Britt, MD, MPH, Gina Curry, BSPH, Robyn Espinosa, BS, Sheila Mahon, BS, Juned Mohammed, BDS, Yashika Watkins, PhD, MPH
October 2016 Vol 7, No 9 | September 23, 2016
Partnerships between churches and universities have emerged as a promising approach for addressing public health inequities. EPICS is a community outreach and screening program.
- 1
- 2
Page 1 of 2
Results 1 - 10 of 16
Results 1 - 10 of 16